ALS remains one of the most difficult neurological diseases to explain. The condition gradually damages the motor neurons that allow people to move, speak, swallow and breathe. Researchers understand far more about the condition than they did a generation ago, but one of the most important questions still has no simple answer: why does one person develop the disease while another does not?
Public awareness has increased after several high-profile cases. Actor Kenneth Mitchell died in February 2024 after living with the disease for more than five years. Photographer Bryan Randall died in August 2023 after a private three-year illness. Actor Eric Dane died in February 2026 after publicly discussing his diagnosis and advocating for greater awareness. These stories have brought attention to a disease that affects thousands of families far from the spotlight.
The science is complex. Most cases do not follow a clear inherited pattern. Some are linked to genetic variants, while researchers continue to investigate environmental, occupational and lifestyle factors. A diagnosis can also be difficult because early symptoms may resemble other conditions.
This article explains what the disease is, what scientists know about possible causes, which uncertainties remain and why recent progress in genetics has created cautious hope.
This article is for general information only. It is not a substitute for medical advice, diagnosis or treatment. Anyone concerned about progressive weakness, speech changes or swallowing difficulties should contact a qualified healthcare professional.
ALS at a Glance
| Question | What current evidence shows |
|---|---|
| What is ALS? | A progressive neurodegenerative disease affecting motor neurons in the brain, brainstem and spinal cord |
| What does it affect? | Voluntary muscle control, including movement, speech, swallowing and breathing |
| Is it contagious? | No |
| Is it inherited? | Most cases are not clearly inherited; roughly 10% to 15% are familial, depending on the source and definition used |
| Is there one known cause? | No. ALS is likely to result from a complex interaction of genetic and non-genetic factors |
| Is there a cure? | No curative treatment currently exists, but therapies and multidisciplinary care can help manage the disease |
| Who should assess possible symptoms? | A doctor, usually with referral to a neurologist |
What Is ALS?
ALS stands for amyotrophic lateral sclerosis. In the United States, it is also commonly called Lou Gehrig’s disease. In the United Kingdom, the broader term motor neurone disease, or MND, is often used, while ALS may refer more specifically to the most common form.
The disease affects motor neurons. These nerve cells carry instructions from the brain and spinal cord to muscles. As motor neurons deteriorate, the muscles they control gradually become weaker. Over time, this can interfere with walking, hand movements, speaking, eating and breathing.
The condition does not progress in exactly the same way for everyone. Some people first notice weakness in a hand, arm, leg or foot. Others experience speech or swallowing problems. A recent JAMA review reported that progressive painless weakness begins in a limb region in about 65% of cases, in muscles affecting speech or swallowing in 20% to 25%, and in axial muscles affecting posture in 5% to 10%.
The variation is one reason the disease can be difficult to recognize early. A single symptom such as muscle twitching does not prove that someone has the disease. Many common conditions can cause similar symptoms. The pattern, progression and clinical examination matter.
How Many People Are Living With ALS?
The condition is rare, but updated surveillance data show that it affects more people in the United States than older estimates sometimes suggested.
The CDC National ALS Registry dashboard lists a 2025 prevalence of 10.1 people per 100,000 in the U.S. population. It also projects that 34,720 adults will be living with the disease in the United States in 2026.
| CDC registry measure | Latest figure shown on the dashboard |
|---|---|
| U.S. prevalence in calendar year 2025 | 10.1 people per 100,000 |
| Projected adults living with the disease in 2026 | 34,720 |
| U.S. incidence in calendar year 2019 | 1.44 new cases per 100,000 |
Surveillance is challenging because the disease is relatively uncommon and data can lag. The registry combines information from government databases and self-enrollment. Its purpose is not only to estimate how many people are affected but also to support research, clinical-trial recruitment and the study of possible risk factors.
Who Is More Likely to Develop ALS?
The disease can affect people from different backgrounds. Most people who develop it are between 40 and 70 years old, with an average age of diagnosis of about 55, according to the ALS Association. Younger adults can also develop the disease.
Men are slightly more likely than women to be diagnosed, although the difference becomes smaller at older ages. Military veterans have also been identified as a group with a higher risk of diagnosis and death from the disease.
These patterns are useful for research, but they do not allow a doctor to predict with certainty who will become ill. The condition is not caused by one easily identifiable behaviour, and many people who develop it do not have an obvious risk factor.
Sporadic ALS and Familial ALS Are Not the Same Thing
One of the clearest distinctions is between sporadic and familial disease.
Most cases are sporadic. This means the person is the only known member of the family with the condition. The ALS Association describes about 90% of cases this way. A recent JAMA review uses a slightly different estimate, describing approximately 85% of cases as sporadic and 15% as familial. The difference reflects how studies define and identify inherited disease.
Familial ALS refers to cases in which the condition appears within a family. A genetic variant can raise risk substantially, but inheritance is not always simple. A family history does not mean every relative will develop the disease. Some variants have incomplete penetrance, meaning a person can carry a variant without developing symptoms.
The distinction is also becoming less rigid. The ALS Association’s genetic-testing guidance states that a known disease-associated variant can be identified in some people who appear to have sporadic disease. In other words, the absence of an obvious family history does not always mean genetics are irrelevant.
Which Genes Are Linked to ALS?
Researchers have associated more than 60 genes with ALS, according to the 2026 JAMA review. Two of the best-known are C9orf72 and SOD1.
| Gene | Why it matters |
|---|---|
| C9orf72 | Pathogenic variants are found in a substantial share of familial cases and can also be associated with frontotemporal dementia |
| SOD1 | Variants account for a smaller share of cases but are especially important because a gene-targeted treatment is available for eligible adults |
| Other genes | Researchers continue to study additional variants and how they affect motor-neuron damage |
The genetics are important, but they are not the whole explanation. Many people with the condition do not have an identified disease-associated variant. Researchers are therefore studying how genes may interact with age, environmental exposures and cellular processes.
Genetic testing is a medical decision, not a consumer quiz. It can affect the person diagnosed as well as relatives who may have questions about their own risk. Anyone considering testing should discuss it with a clinician and, where available, a genetic counsellor.
Why Do Motor Neurons Become Damaged?
The condition is better understood as a group of interacting biological problems than as a disease with one universal trigger.
Scientists are studying several mechanisms:
- abnormal protein processing and accumulation;
- disrupted transport of materials inside nerve cells;
- oxidative stress and cellular damage;
- inflammation involving cells that support or surround neurons;
- problems with RNA processing;
- glutamate-related excitotoxicity;
- mitochondrial dysfunction;
- genetic variants that alter how motor neurons function or survive.
These mechanisms can overlap. Different pathways may lead to a similar result: progressive loss of motor neurons. That helps explain why two people can develop similar clinical symptoms even when their underlying biology is not identical.
This complexity also affects treatment research. A therapy that helps one genetic subgroup may not work in the same way for everyone else. Precision medicine is therefore becoming an increasingly important part of ALS research.
Are Environmental Exposures Involved?
Researchers continue to investigate environmental and occupational factors, but the evidence requires careful wording.
The ALS Association’s risk-factor overview says genetics, environmental exposures and lifestyle or occupational choices have been linked to increased risk. Researchers have examined subjects such as military service, some chemical exposures, heavy metals, pesticides, smoking, physical activity and traumatic injury.
A link is not the same as proof that one exposure caused a specific person’s illness. Studies can identify patterns without explaining every case. Exposure levels may be difficult to measure accurately years later. Different factors may also interact.
For readers, the practical message is important: there is no single proven lifestyle change that guarantees prevention. General healthy lifestyle habits remain valuable for overall wellbeing, but nobody should be blamed for developing ALS.
Common Early Signs
Symptoms differ from person to person and usually worsen over time. The Mayo Clinic lists possible early signs including weakness, tripping, hand clumsiness, slurred speech, swallowing difficulty, cramps and twitching.
Possible symptoms include:
- weakness in a hand, arm, leg, foot or ankle;
- repeated tripping or difficulty with ordinary tasks;
- reduced grip strength or hand clumsiness;
- muscle cramps or twitching alongside weakness;
- stiffness or spasticity;
- slurred speech;
- difficulty swallowing;
- inappropriate laughing, crying or yawning in some people;
- changes in thinking or behaviour in some cases.
These symptoms are not specific to the disease. Many have more common explanations. A professional assessment is important when weakness is progressive, unexplained or spreading.
Why Diagnosis Can Take Time
There is no single stand-alone test that proves a person has the disease.
A neurologist assesses the history of symptoms, examines muscle strength and reflexes, and may use electromyography, often called EMG, to evaluate electrical activity in muscles. Nerve-conduction studies, imaging, blood tests and other assessments may help rule out conditions that can resemble ALS.
The 2026 JAMA review explains that diagnosis is based on clinical features and can be supported by EMG results. The process can be frustrating because early symptoms may be subtle. However, careful assessment matters: doctors need to distinguish ALS from treatable conditions that may present with similar signs.
A person worried about symptoms should not attempt to diagnose themselves through an online checklist. They should contact a healthcare professional.
What Treatments Are Available?
There is currently no cure, but treatment is not the same as doing nothing.
A 2026 JAMA review describes three U.S. Food and Drug Administration-approved disease-modifying therapies: riluzole, edaravone and tofersen. Riluzole and edaravone modestly slow progression for some patients. Tofersen is a gene-targeted antisense treatment for adults with an SOD1 variant.
The FDA’s Qalsody page explains that tofersen targets SOD1 messenger RNA to reduce production of the SOD1 protein. It was approved under the accelerated-approval pathway based on a reduction in neurofilament light, a biomarker linked to nerve injury and neurodegeneration.
Medication decisions must be made with a specialist. The right option depends on the person’s diagnosis, genetics, health, symptoms and treatment goals.
Why Multidisciplinary Care Matters
Medical care goes beyond disease-modifying medication.
The disease can affect movement, communication, nutrition and breathing. A coordinated team may include neurologists, nurses, respiratory specialists, physiotherapists, occupational therapists, speech and language professionals, dietitians, social workers and palliative-care specialists.
The recent JAMA review reports that specialized multidisciplinary teams are associated with improved survival and quality of life. Support can include:
- mobility equipment and home adaptations;
- communication devices;
- respiratory monitoring and breathing support;
- help with nutrition and swallowing;
- symptom management;
- emotional support for patients and families;
- planning that respects the person’s wishes.
Care should be individualized. The disease can progress at different speeds, and priorities can change over time.
Why Stephen Hawking’s Story Was Unusual
Stephen Hawking is often mentioned in discussions of ALS because he lived for decades after developing motor-neuron disease as a young adult.
His experience was exceptional. It should not be used to predict the course of the illness for another person.
The JAMA review reports mean survival of three to five years after diagnosis, but averages do not describe every individual. Some people live for shorter periods, while others live considerably longer. The rate of progression, age, site of symptom onset and individual biology can all matter.
Hawking’s story demonstrates variability, not a typical outcome.
Why Public Awareness Still Matters
The deaths of Kenneth Mitchell, Bryan Randall and Eric Dane brought public attention to ALS for different reasons.
Mitchell spoke openly about adapting to life with the disease and continued working after his diagnosis. Randall’s family said he chose to keep his illness private. Dane used the period after announcing his diagnosis to advocate for awareness and research.
There is no single correct way for a person or family to respond publicly. Some want privacy. Others use their platform to support research, funding or care. Both choices deserve respect.
Awareness matters when it leads people toward reliable information rather than fear. It can support research participation, improve understanding of symptoms and reduce the isolation experienced by families.
Research Is Moving Toward More Precise Answers
The unanswered questions remain substantial, but research is becoming more targeted.
The National ALS Registry helps researchers estimate prevalence, recruit participants and study risk factors. Genetic research is identifying subgroups that may respond to specific therapies. Biomarker research is exploring measurable signs of nerve injury and disease progression. Clinical trials are testing treatments through more efficient designs.
Important research questions include:
- Why do some genetic variants cause disease in one carrier but not another?
- Which environmental exposures meaningfully change risk?
- Can biomarkers detect disease earlier or track progression more accurately?
- Can gene-targeted therapies help additional subgroups?
- How can clinical trials move faster while remaining rigorous?
- Which combinations of treatments may be most effective?
The progress is real, but it should not be overstated. The condition remains a devastating illness without a cure. Hope is strongest when it is tied to evidence, careful research and access to high-quality care.
What Readers Should Remember
ALS is a progressive neurological disease affecting motor neurons. It is not contagious. It is not caused by one simple mistake or lifestyle choice. Most cases do not show a clear family history, although genetics can still play an important role.
The most useful summary is balanced:
- Most cases are sporadic.
- A smaller share are familial.
- More than 60 genes have been associated with the condition.
- Environmental and occupational risk factors remain under investigation.
- There is no single diagnostic test.
- There is no cure, but therapies and multidisciplinary care can help.
- New gene-targeted treatments show why research matters.
The mystery is not solved. Researchers are gradually replacing uncertainty with more precise questions and better tools.
For more evidence-based health coverage, read our healthy lifestyle guide and follow The News Ink on Instagram or its WhatsApp channel.
